Nexalin Gen-1

Clears FDA for the treatment of Anxiety, Depression and Insomnia. Nexalin is presently analyzing prior FDA applications to determine new regulatory strategies for the treatment of Insomnia.

2020 Q1

Nexalin Gen-1

Nexalin begins analyzing 510K application process for Anxiety and Insomnia (postpones Depression PMA)

2020 Q4

China A,D

Nexalin develops and begins research on the China A,D (Alzheimer's and Dementia)

2021 Q2

Nexalin Gen-2

Nexalin develops the Nexalin Gen-2 medical device and begins research with new advanced waveform

2021 Q2

China A,D,I

Nexalin approved by China NMPA for treatment of Depression and Insomnia

2022 Q3

Patient Headset

Nexalin’s Gen-3 technology will be imbedded into a new patient headset medical device. Image is a prototype image.